HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer.

AbstractBACKGROUND:
Pulmonary large cell neuroendocrine carcinoma (LCNEC) shares several features with small cell lung carcinoma (SCLC). Most histologic diagnoses of LCNEC are currently obtained by surgical specimens. While the diagnosis of LCNEC by biopsy specimens is challenging, a definitive diagnosis of this highly malignant tumor is critical in unresectable cases to determine the optimal therapeutic strategy. The objective of this study was to assess the efficacy of chemotherapy for unresectable high-grade non-small cell neuroendocrine carcinoma (HNSCNEC) called by us, which likely includes most LCNECs except for combined types, and to compare the efficacy of chemotherapy for HNSCNEC, with that for extended disease SCLC (ED-SCLC).
METHODS:
Between September 2002 and October 2007, we reviewed 14 patients with HNSCNEC, which was defined using biopsy specimens according to histological and immunohistological criteria proposed by us. We simultaneously evaluated the clinical response to the chemotherapy and survival time of the 14 HNSCNEC and 77 ED-SCLC patients.
RESULTS:
The chemotherapy regimens in the 14 patients with unresectable HNSCNEC were platinum-based combination regimens or irinotecan or vinorelbine or docetaxel alone. The chemotherapy regimens in the 77 patients with ED-SCLC were platinum-based combination regimens. We assessed an objective response rate, a one-year survival rate, and median survival time as 50% (7/14), 34% and 10 months, respectively, in the 14 HNSCNEC patients, and as 53% (41/77), 48% and 12.3 months, respectively, in the 77 ED-SCLC patients.
CONCLUSION:
The clinical efficacy of chemotherapy for unresectable HNSCNECs, including most LCNECs, is comparable to that for ED-SCLC.
AuthorsSatoshi Igawa, Reiko Watanabe, Ichiro Ito, Haruyasu Murakami, Toshiaki Takahashi, Yukiko Nakamura, Asuka Tsuya, Kyoichi Kaira, Tateaki Naito, Masahiro Endo, Nobuyuki Yamamoto, Toru Kameya
JournalLung cancer (Amsterdam, Netherlands) (Lung Cancer) Vol. 68 Issue 3 Pg. 438-45 (Jun 2010) ISSN: 1872-8332 [Electronic] Ireland
PMID19699548 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright 2009 Elsevier Ireland Ltd. All rights reserved.
Chemical References
  • Platinum Compounds
  • Taxoids
  • Docetaxel
  • Vinblastine
  • Irinotecan
  • Vinorelbine
  • Camptothecin
Topics
  • Aged
  • Aged, 80 and over
  • Camptothecin (administration & dosage, adverse effects, analogs & derivatives)
  • Carcinoma, Non-Small-Cell Lung (diagnosis, drug therapy, mortality, pathology, physiopathology)
  • Disease Progression
  • Docetaxel
  • Drug Therapy, Combination
  • Female
  • Humans
  • Immunohistochemistry
  • Irinotecan
  • Lung Neoplasms (diagnosis, drug therapy, mortality, pathology, physiopathology)
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Neuroendocrine Tumors (diagnosis, drug therapy, mortality, pathology, physiopathology)
  • Platinum Compounds (administration & dosage, adverse effects)
  • Survival Analysis
  • Taxoids (administration & dosage, adverse effects)
  • Vinblastine (administration & dosage, adverse effects, analogs & derivatives)
  • Vinorelbine

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: